DOMPE FARMACEUTICI SPA

Their core work

Dompé is an Italian pharmaceutical company headquartered in Milano that specializes in drug discovery and development, with a strong computational approach using high-performance computing (HPC) and AI-driven molecular simulations. They operate at the intersection of pharma and supercomputing, applying exascale platforms to accelerate drug design, repurposing, and screening — most visibly in their rapid COVID-19 response. Their H2020 portfolio shows them contributing both deep pharma domain expertise and industrial use cases for HPC research.

What they specialise in

How they've shifted over time

Dompé's H2020 trajectory shows a clear pivot from general HPC infrastructure to applied computational pharma. Their early projects (2015-2018) focused on programming methodologies, compilers, and adaptive runtime systems for heterogeneous computing — essentially contributing as an industrial end-user for HPC research. From 2020 onward, they shifted decisively into drug discovery, drug repurposing, and AI-driven molecular design, taking coordinator roles and applying HPC directly to pharmaceutical problems including the COVID-19 emergency response.

Dompé is moving toward AI-powered, exascale drug discovery platforms — expect them to seek partners with machine learning, molecular dynamics, or clinical validation capabilities.

How they like to work

Dompé operates as both a project leader and an industrial partner, having coordinated 2 of their 5 projects (both in the drug discovery space). They engage in large consortia — 153 unique partners across 35 countries indicates broad networking rather than tight recurring clusters. Their third-party role in EUROCC and partner role in INCIPIT suggest they also selectively contribute domain expertise to projects led by others, particularly in HPC and training contexts.

With 153 unique consortium partners across 35 countries, Dompé has one of the broadest collaboration networks for a private pharma company in H2020. Their reach spans nearly all of Europe and beyond, reflecting the large-scale nature of HPC and pandemic-response consortia.

What sets them apart

Dompé occupies a rare position as a pharmaceutical company that genuinely understands and drives HPC and AI infrastructure for drug discovery — not just as a passive end-user but as a coordinator building the platforms. Their COVID-19 response with EXSCALATE4CoV demonstrated the ability to mobilize a massive consortium rapidly for urgent drug repurposing. For consortium builders, they offer the combination of real pharma industry needs with deep computational expertise, bridging a gap that few private companies can.

Highlights from their portfolio

• EXSCALATE4CoV
  Dompé-coordinated rapid-response project applying their exascale drug screening platform to COVID-19, combining structural biology with computational repurposing at unprecedented scale.
• LIGATE
  Dompé-coordinated platform project integrating AI/ML with molecular dynamics at exascale — represents their strategic direction and the maturation of capabilities built across earlier HPC projects.
• ANTAREX
  Their earliest H2020 project, revealing the HPC roots that later evolved into their drug discovery platform work — shows the long arc of capability building.